NFKB1 and non-small cell lung carcinoma: Our prior research demonstrated the effect of FGFC1 to reverse drug resistance in erlotinib-resistant non-small cell lung cancer and regulate the NF-κB signaling pathway which plays a well-known role in regulating immune response and inflammation, highlighting its therapeutic promise (Feng et al., 2022; Yan et al., 2022).